Seeking Alpha
 

St. Jude Medical, Inc. (STJ)

- NYSE
Show Summaries  |  Hide Summaries
  • Jun. 18, 2012, 1:10 PM
    Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata defibrillator cable. A report turned up in an FDA database and was said to be due to a fraying issue, prompting fears that problems with STJ's earlier Riata product may not be isolated. But anyone can file to that database, Lazard says, and the cable wasn't returned to STJ for analysis.
    | 3 Comments
  • Jun. 14, 2012, 7:32 PM
    A class action lawsuit charges St. Jude Medical (STJ) with misrepresenting facts around the company's Riata and Riata ST defibrillator leads (discontinued last year). Plaintiffs say protruding wires on those and other products caused short circuits that the company failed to disclose.
    | Comment!
  • Jun. 12, 2012, 12:44 PM
    St. Jude Medical (STJ -5.5%) shares plunge suddenly on a report that the company's Durata defribilator is linked to a cable defect. STJ has had a similar problem with its Riata lead, which is no longer on the market; the company has said Durata leads, which it still sells, don't have the problem because they use a different type of insulation material.
    | Comment!
  • May 31, 2012, 5:05 PM
    Dividend yields look increasingly attractive vs. record low Treasury yields, and Morgan Stanley argues the payout ratio of dividend stocks is near an all-time low and could increase substantially. The firm adds T to its dividend portfolio while removing XOM and UNP; "fundamentally and quantitatively attractive" are CVX, MET, FCX, BEN, CAH, FITB, STJ, SPLS.
    | 4 Comments
  • May 14, 2012, 1:26 PM
    St. Jude Medical (STJ +2.1%) ticks higher after being upgraded to Buy at Goldman. The firm cites share gains in its core markets and entrance into new therapeutic categories, which could accelerate revenue growth through 2015. It also raises its price target to $50 from $45.
    | Comment!
  • May 9, 2012, 3:08 PM
    St. Jude Medical (STJ +3.5%) trades up after the FDA approves its Ellipse implantable cardioverter defibrillator. Designed with feedback from more than 200 physicians, the Ellipse offers physicians unique advancements, and is designed to increase patient comfort and physician ease-of-use. Separately, Morgan Stanley upgraded the shares to Overweight this morning, saying it expects the company to benefit from new cardio markets and reduced Durata concerns.
    | Comment!
  • May 2, 2012, 10:40 AM
    Edwards Lifesciences (EW +0.9%) shrugs off this mornings weakness after the Centers for Medicare & Medical Services announced it will cover Transcatheter Aortic Valve Replacement procedures for the treatment of symptomatic aortic valve stenosis, for which EW's Sapien is a marquee product. Separately, Wells Fargo ups the shares to Outperform on the news.
    | Comment!
  • May 1, 2012, 11:49 AM
    New J&J (JNJ) CEO Alex Gorsky is looking to strengthen the company's medical-device unit via takeovers, he tells Bloomberg in an interview. "We remain committed to cardiovascular," Gorsky says, despite sales shrinking 44% since 2006. On the analyst wish list are Edwards Lifesciences (EW) and St. Jude Medical (STJ).
    | 2 Comments
  • May 1, 2012, 11:10 AM
    The problems related to the wires of St Jude Medical's (STJ +0.5%) Riata implantable defibrillator, which was recalled late last year, have continued over the past 3 months, a new report shows. The silicone coating around the wire lead eroded at an estimated 0.3% rate, although the report's authors say the figure could be higher.
    | Comment!
  • Apr. 23, 2012, 9:56 AM
    Abbott Laboratories (ABT -0.55%) and St Jude Medical (STJ -1.8%) expand a 2008 agreement to jointly promote each others' cardiovascular products in the U.S. and offer a full complement of devices. Abbot will provide heart stents and St Jude systems that correct irregular heartbeats such as pacemakers.
    | Comment!
  • Apr. 18, 2012, 8:25 AM
    Shares of St. Jude Medical (STJ) move up 0.9% in premarket trading after beating the earnings estimates of analysts with its Q1 report. The firm expects Q2 EPS 2012 of $0.86-$0.88 per share and full-year EPS of $3.44-$3.49 with new products in its pipeline set to be launched.
    | Comment!
  • Apr. 18, 2012, 7:44 AM
    St. Jude Medical (STJ): Q1 EPS of $0.86 beats by $0.03. Revenue of $1.4B (+1.4% Y/Y) in-line. (PR)
    | Comment!
  • Apr. 18, 2012, 12:05 AM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 5:30 PM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 1:21 PM
    Canaccord is recommending buying St. Jude Medical (STJ +2%) ahead of its upcoming Q1 report. The firm sees an in-line quarter but feels 2012 guidance is too conservative, saying that with signs of CRM stabilization and new product pipelines, the stocks recent weakness presents a decent buying opportunity for longer-term investors.
    | Comment!
  • Apr. 9, 2012, 2:33 PM
    St. Jude Medical (STJ -4.8%) shares sink after calling attention to a medical journal article that shows Medtronic's (MDT -0.9%) heart device leads resulted in fewer deaths than its recalled Riata and Riata ST products. STJ says the article "substantially undercounted" deaths associated with MDT's Quattro Secure device and wants it retracted.
    | Comment!
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.